Outlook Therapeutics Inc
NASDAQ:OTLK

Watchlist Manager
Outlook Therapeutics Inc Logo
Outlook Therapeutics Inc
NASDAQ:OTLK
Watchlist
Price: 0.4671 USD -6.05%
Market Cap: $20.7m

Operating Margin

-4 744.4%
Current
Improving
by 40.1%
vs 3-y average of -4 784.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-4 744.4%
=
Operating Income
$-67.1m
/
Revenue
$1.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-4 744.4%
=
Operating Income
$-67.1m
/
Revenue
$1.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Outlook Therapeutics Inc
NASDAQ:OTLK
21.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-4 744.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Outlook Therapeutics Inc
Glance View

Market Cap
20.7m USD
Industry
Biotechnology

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 9 full-time employees. The company went IPO on 2016-06-13. The firm focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

OTLK Intrinsic Value
1.0746 USD
Undervaluation 57%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-4 744.4%
=
Operating Income
$-67.1m
/
Revenue
$1.4m
What is Outlook Therapeutics Inc's current Operating Margin?

The current Operating Margin for Outlook Therapeutics Inc is -4 744.4%, which is above its 3-year median of -4 784.5%.

How has Operating Margin changed over time?

Over the last 4 months, Outlook Therapeutics Inc’s Operating Margin has increased from -4 824.6% to -4 744.4%. During this period, it reached a low of -4 824.6% on Jun 30, 2025 and a high of -4 744.4% on Oct 30, 2025.

Back to Top